What question did this study set out to answer?

The aim is to clarify the association between endocrine immune-related adverse events and progression-free survival in advanced non-small cell lung cancer.

April 26, 2026Frontiers in Oncology0 citationsOpen Access

Correction: Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib

FSFurong Sun YGYuzhu Gao XZXiaoyan Zheng

Key Points

The aim is to clarify the association between endocrine immune-related adverse events and progression-free survival in advanced non-small cell lung cancer.
Correction made to supplementary material in the published article.
Table1.xlsx was incorrectly linked and has been removed.
No specific outcomes or results are reported due to the nature of the correction.

Abstract

Correction on: Sun F, Gao Y, Zheng X, Hua J, Liu S, Cao D and Zhou J (2026) Association of endocrine immune-related adverse events with progression-free survival in advanced nonsmall cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib. Front. Oncol. 16:1701750. doi: 10.3389/fonc.2026.1701750In the published article, file "Table1.xlsx" was erroneously associated with the published article record as supplementary material. The file has now been removed.The original version of this article has been updated.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Sun et al. (Wed,) studied this question.

synapsesocial.com/papers/69edaafc4a46254e215b33dd https://doi.org/https://doi.org/10.3389/fonc.2026.1847088

AI से पूछें

Bookmark

View Full Paper